Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
This is an extension study for women who have already received six months of treatment in the phase III clinical trial M12-815 (NCT02654054) or M12-817 (NCT02691494), and will evaluate the long-term efficacy and safety of elagolix administered alone and in combination with estradiol/norethindrone acetate for an additional six months in the treatment of heavy menstrual bleeding associated with uterine fibroids.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20010, United States
Washington D.C., District of Columbia 20011, United States
Southfield, Michigan 48034, United States
Neptune City, New Jersey 07753-4859, United States
Greensboro, North Carolina 27408, United States
Hershey, Pennsylvania 17033, United States
Menphis, Tennessee 38104, United States